1 / 2

AstraZeneca inks $6.9-bn breast, gastric cancer therapy deal with Daiichi

Read more about AstraZeneca inks $6.9-bn breast, gastric cancer therapy deal with Daiichi on Business Standard. AstraZeneca said the transaction won't impact earnings this year but will make a 'significant contribution' by 2023

dorothygracious
Download Presentation

AstraZeneca inks $6.9-bn breast, gastric cancer therapy deal with Daiichi

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. AstraZeneca inks $6.9-bn breast, gastric cancer therapy deal with Daiichi AstraZeneca said the transaction won't impact earnings this year but will make a 'significant contribution' by 2023 International News a promising malignant growth treatment in its greatest arrangement in over 10 years as it means to turn into a worldwide oncology powerhouse. : AstraZeneca Plc consented to pay up to $6.9 billion for a bit of AstraZeneca will pay the Japanese drugmaker Daiichi Sankyo Co. $1.35 billion forthright to together create and market the malignant growth treatment trastuzumab deruxtecan, with as much as $5.6 billion in extra installments subject to deals achievements and different possibilities, the organizations said late Thursday. They will likewise similarly part advancement and commercialization costs.

  2. The Cambridge, U.K.- based organization said it will finance the exchange halfway through an offer clearance of up to $3.5 billion. Daiichi Sankyo shares flooded 16 percent - the stock's every day limit - to an untouched high in early Tokyo exchanging Fridayh.Read More Business Standard

More Related